Research programme: severe pain therapeutic - Relevare

Drug Profile

Research programme: severe pain therapeutic - Relevare

Alternative Names: CNSB 004; Leconotide - Relevare

Latest Information Update: 01 Sep 2015

Price : $50

At a glance

  • Originator CNSBio
  • Developer Relevare Pharmaceuticals
  • Class Non-opioid analgesics; Peptides; Venoms
  • Mechanism of Action N-type calcium channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Pain

Most Recent Events

  • 07 Oct 2008 Preclinical trials in Pain in Australia (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top